论文部分内容阅读
目的观察在西药治疗的基础上加用活血化浊胶囊对不稳定性心绞痛患者C反应蛋白(C reactive protein,CRP)、血小板凝聚率和症候积分的影响。方法使用随机数字表法将符合纳入标准的2014年6月—2015年6月青海大学附属医院收治的60例患者随机分为治疗组、对照组,每组30例。2组患者在基础治疗的同时,给予单硝酸异山梨酯40 mg静点1次/d;治疗组同时加服活血化浊胶囊,3粒/次,3次/d;治疗后进行疗效性指标的观察。组间比较采用t检验(2组间为两独立样本t检验,同组治疗前后采用配对样本t检验);等级资料用Ridit检验。结果治疗组心绞痛治疗疗效优于对照组,差异具有统计学意义(P<0.05)。心电图比较,治疗组和对照组差异无统计学意义(P>0.05)。2组间治疗前后中医症候积分差异有统计学意义(P<0.05)。2组间治疗前后CRP差异有统计学意义(P<0.05),且治疗组优于对照组(P<0.05)。2组间治疗前后血小板凝聚率差异有统计学意义(P<0.01),且治疗组优于对照组(P<0.01)。结论通过实验活血化浊胶囊可降低C反应蛋白(CRP),稳定斑块,改善血小板凝聚率,预防血栓发生,可以加强抗动脉粥样硬化的作用,预防心绞痛的发生。
Objective To observe the effects of Huoxuehuazhu capsule on C reactive protein (CRP), platelet aggregation rate and symptom score in patients with unstable angina pectoris on the basis of western medicine. Methods Sixty patients admitted to Affiliated Hospital of Qinghai University from June 2014 to June 2015 were randomly divided into treatment group and control group, with 30 cases in each group. Two groups of patients were treated with isosorbide mononitrate 40 mg intravenously once a day while basic treatment was given. The treatment group was treated with Huoxue Huazao Capsule at the same time, 3 capsules / time, 3 times / d. The curative effect index Observation. The t-test was used to compare the two groups (two independent samples t-test between the two groups, paired samples t-test before and after treatment); Ridit test. Results The curative effect of angina pectoris in treatment group was better than that in control group, the difference was statistically significant (P <0.05). Electrocardiogram comparison, the treatment group and the control group no significant difference (P> 0.05). The difference of TCM symptom scores between the two groups before and after treatment was statistically significant (P <0.05). The difference of CRP between the two groups before and after treatment was statistically significant (P <0.05), and the treatment group was better than the control group (P <0.05). The difference of platelet aggregation between the two groups before and after treatment was statistically significant (P <0.01), and the treatment group was better than the control group (P <0.01). Conclusion The experimental Huoxuehuazhuo Capsule can reduce C-reactive protein (CRP), plaque stability, improve platelet aggregation rate and prevent thrombosis, can enhance the role of anti-atherosclerosis, prevention of angina pectoris.